Telesis Bio Inc. announced a new licensing agreement with Regeneron Pharmaceuticals to deploy its revolutionary Gibson SOLA platform at Regeneron's R&D core facilities. The partnership aims to enable automated, high-throughput, on-demand gene synthesis capabilities within Regeneron's laboratories, potentially transforming the company's approach to biologics discovery.
Platform Technology Breakthrough
The Gibson SOLA platform represents a significant advancement in nucleic acid synthesis technology. The system enables fully-enzymatic, overnight, on-site synthesis of extremely high-fidelity DNA and mRNA, dramatically reducing design-to-build timelines from weeks to hours. This acceleration empowers researchers to iterate faster while maintaining tighter intellectual property control and streamlining complex workflows that were previously reliant on external service providers.
"Regeneron is one of the most forward-thinking biotechnology companies and is known for pushing the boundaries of scientific discovery and accelerating drug development," said Eric Esser, CEO of Telesis Bio. "Adopting the Gibson SOLA platform is intended to enable full control of the nucleic acid supply-chain and allows Regeneron to gain new insights that can aid in drug development."
Industry Transformation
The agreement reflects a broader industry shift toward gaining competitive advantages through internalizing synthetic biology capabilities. This strategic move aims to increase velocity, enhance data security, and drive AI-powered drug discovery initiatives. The Gibson SOLA platform addresses these industry needs by allowing scientists to perform long, complex nucleic acid synthesis using standard laboratory automation, effectively eliminating the delays and limitations associated with traditional methods.
Technical Capabilities
The recently launched proprietary Gibson SOLA platform functions as a reagent platform with a comprehensive suite of software tools that can be easily adopted at nearly any scale and throughput. This flexibility enables customers to take complete control of their nucleic acid supply chain from design to final molecule. The platform allows organizations to break free from the constraints and complexity of external supply chains while maintaining data security.
The highly flexible platform can be deployed on various standard liquid-handling automation solutions and optimized for a range of applications, including biologics, vaccines, and cell and gene therapy. Gibson SOLA demonstrates high efficiency and produces extremely high-fidelity and high-purity DNA, enabling customers to move away from cumbersome cloning and confirmation workflows while significantly improving productivity and speed.
Broader Applications
The technology supports innovation across multiple therapeutic areas, including precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. The platform, combined with Telesis Bio's award-winning BioXp systems, enables rapid, accurate, and reproducible writing of DNA and mRNA, automating and optimizing the entire synthesis, cloning, and amplification workflow within customer laboratories.
Scientists worldwide are leveraging this technology to accelerate the design-build-test paradigm, driving innovation across various fields addressing humanity's greatest challenges. The non-toxic, high-fidelity, and scalable DNA synthesis capabilities position the platform as a transformative tool in the synthetic biology landscape.
